CardioExchange Archive

March 23rd, 2015

Selections from Richard Lehman’s Literature Review: March 23rd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include antiplatelet therapy duration following bare metal or drug-eluting coronary stents, thrombolysis in acute ischemic stroke, and more.

---

February 10th, 2014

FDA Reviewers Deliver Split Opinion on Cangrelor

Larry Husten, PHD

FDA reviewers presented two dramatically different views of The Medicines Company’s investigational new drug cangrelor. One reviewer says the drug should not be approved without a new trial and even states that the CHAMPION trials “were conducted unethically” and provide sufficient reason to “refuse approval…on that fact alone.”  But two other reviewers recommend approval. On Wednesday the FDA’s Cardiovascular and […]

---

October 7th, 2013

Study Supports Loosening Guidelines for Surgery After Stent Implantation

Larry Husten, PHD

According to current guidelines, noncardiac surgery should be delayed for six weeks after bare-metal stent (BMS) implantation and for one year after drug-eluting stent (DES) implantation, though there is little good evidence to support these recommendations. Stent thrombosis caused by discontinuation of antiplatelet therapy in order to lower the risk of bleeding during surgery is the […]

---

September 12th, 2013

Aspirin Therapy with Anticoagulation in Patients with Afib?

Benjamin A. Steinberg, MD and John Ryan, MD

An interview with Benjamin Steinberg about an analysis of data from the ORBIT-AF registry, in which patients with atrial fibrillation who were taking oral anticoagulation and aspirin had a higher risk of bleeding than patients on anticoagulation only.

---

May 24th, 2013

Rivaroxaban Gains Approval in Europe for ACS Indication

Larry Husten, PHD

Rivaroxaban (Xarelto, Bayer) has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction, or stroke) following an acute coronary syndrome (ACS). The drug was approved at a dose of 2.5 mg twice-daily and should be used in combination with standard antiplatelet therapy. Rivaroxaban is now the only oral anticoagulant to receive […]

---

March 11th, 2013

Selections from Richard Lehman’s Literature Review: March 11th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include antiplatelet therapy to prevent CV events and mortality in those with intermittent claudication, endovascular treatment for stroke, and more.

---

February 14th, 2013

No Aspirin After DES? Is This The Wild, Wild WOEST?

Richard A. Lange, MD, MBA and L. David Hillis, MD

According to the recently published results of the WOEST trial, patients receiving anticoagulation thereapy who undergo stenting have better outcomes with clopidogrel only than with clopidogrel plus aspirin. Rick Lange and David Hillis ask: Are you ready to stop prescribing aspirin to these patients?

---

December 3rd, 2012

Selections from Richard Lehman’s Literature Review: December 3rd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.

---

November 4th, 2012

Platelet-Function Testing in Coronary Stenting: Frozen in Its Tracks

Gilles Montalescot, MD, PhD

An ARCTIC trial investigator discusses possible reasons why antiplatelet-drug and dosing adjustments, guided by platelet-function testing, did not improve clinical outcomes for stented patients.

---

October 8th, 2012

Triple Antithrombotic Therapy: What — and When — Is the Bleeding Risk?

Morten Lamberts, MD and John Ryan, MD

Morten Lamberts, MD, lead investigator of a recent registry study of various combinations of antithrombotic agents in patients with AF and CAD, answers John Ryan’s questions about the study and its implications.

---